Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genetic determinants of venetoclax resistance

ABSTRACT: Genetic determinants of venetoclax resistance

PROVIDER: PRJNA528105 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8754400_1.fastq.gz	Fastqsanger.gz
	SRR8754400_2.fastq.gz	Fastqsanger.gz
	SRR8754410_1.fastq.gz	Fastqsanger.gz
	SRR8754410_2.fastq.gz	Fastqsanger.gz
	SRR8754420_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 88

Similar Datasets

Genetic determinants of venetoclax resistance

Project description:Resistance to the first approved BCL-2 inhibitor venetoclax is emerging in lymphoid malignancies. The study aimed to identify the genetic determinants of such resistance. From genome-scale screens we determined the genes influencing the sensitivity to BCL-2 inhibition. The present set of data is related to expression changes (assessed by RNA sequencing) observed in the resistant OCI-Ly1 lymphoma cell line as well as those resulting from genetic perturbation (using CRISPR-Cas9) targeting the genes highlighted in our genome-scale screen.

2019-09-25 | GSE128563 | GEO

Determinants of venetoclax resistance

Project description:Determinants of venetoclax resistance

| PRJNA558091 | ENA

Determinants of venetoclax resistance

Project description:Determinants of venetoclax resistance

| PRJNA558092 | ENA

Assessing DNA methylation differences upon aquired Venetoclax resistance

Project description:We analyzed DNA methylation alterations upon acquired Venetoclax resistance using 8 different cell line pairs

2023-11-22 | GSE166577 | GEO

Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

Project description:Venetoclax is the first example of personalized medicine for multiple myeloma (MM), with meaningful clinical activity as a monotherapy and in combination in myeloma patients harboring the t(11:14) translocation. However, despite the high response rates and prolonged PFS, a significant proportion of patients eventually relapse. Here, we aimed to study adaptive molecular responses after the acquisition of venetoclax resistance in sensitive t(11:14) MM cell models. We therefore generated single-cell venetoclax-resistant t(11:14) MM cell lines and investigated the mechanisms contributing to resistance as well as the cells’ sensitivity to other treatments. Our data suggests that acquired resistance to venetoclax is characterized by reduced mitochondrial priming and changes in BCL-2 family proteins’ expression in MM cells, conferring broad resistance to standard-of-care anti-myeloma drugs. However, our results show that the resistant cells are still sensitive to immunotherapeutic treatments, highlighting the need to consider appropriate sequencing of these treatments following venetoclax-based regimens.

2024-06-06 | GSE269245 | GEO

Genetic determinants of antidepressant response

Project description:Genetic determinants of antidepressant response

| PRJNA988901 | ENA

Genetic determinants of antidepressant response

Project description:Genetic determinants of antidepressant response

| PRJNA988902 | ENA

Genetic and epigenetic determinants of neurogenesis and myogenesis

Project description:This SuperSeries is composed of the following subset Series: GSE34906: Genetic and epigenetic determinants of neurogenesis and myogenesis [ChIP-seq] GSE34907: Genetic and epigenetic determinants of neurogenesis and myogenesis [expression profiling] Refer to individual Series

2012-03-26 | E-GEOD-34908 | biostudies-arrayexpress

Assessing DNA methylation differences upon aquired Venetoclax resistance

Project description:Assessing DNA methylation differences upon aquired Venetoclax resistance

| PRJNA701295 | ENA

Effect of venetoclax, tedizolid, and combination treatment on gene expression in a venetoclax-resistant AML cell line

Project description:The goal of this study was to profile the changes in gene expression in an AML cell line with acquired resistance to venetoclax in response to treatment with venetoclax, tedizolid, or combination of the 2 drugs.

2019-08-20 | GSE136032 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data